Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HAT1 | O14929 | 7/20 | 0.36 |
| ▸ | EP300 | Q09472 | 7/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032664 | 0.89 | RAB9A (0.42) | RAB9ANPC1HAT1EP300 | |
| SCHEMBL4357051 | 0.88 | RAB9A (0.43) | RAB9ANPC1 | |
| SCHEMBL3938881 | 0.87 | RAB9A (0.42) | RAB9ANPC1EPHX1 | |
| SCHEMBL3942177 | 0.87 | MDM2 (0.43) | RAB9ANPC1 | |
| SCHEMBL3943464 | 0.87 | ALDH1A1 (0.44) | RAB9ANPC1 | |
| SCHEMBL3939702 | 0.86 | RAB9A (0.42) | RAB9ANPC1 | |
| SCHEMBL3949749 | 0.86 | RAB9A (0.41) | RAB9ANPC1EPHX1BCHE | |
| SCHEMBL3945345 | 0.85 | ALDH1A1 (0.42) | RAB9ANPC1 | |
| SCHEMBL3943978 | 0.85 | RAB9A (0.58) | RAB9ANPC1 | |
| SCHEMBL3941454 | 0.85 | RAB9A (0.58) | RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263720-B1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2009-06-03 | — | — | EP | claimed |
| WO-2009019508-A1 | CALCIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-02-12 | — | — | WO | claimed |
| EP-1263720-B1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009019508-A1 | CALCIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1649849-A2 | Compositions for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates the dopaminergic neurotransmission in the brain. | Aventis Pharma S.A. (FR) | 2006-04-26 | — | — | EP | disclosed |
| EP-1423145-A1 | COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | Aventis Pharma S.A. (FR) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020314-A1 | COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | AVENTIS PHARMA S.A. (FR) | 2003-03-13 | — | — | WO | disclosed |
| EP-1263720-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |